Early Responses in More Patients With Gleevec®1

• The data were analyzed using a Kaplan-Meier approach.

• MCR was more rapid with Gleevec (median time 3 months, range 2.2 to 17 months) than with

IFN-α + ara-C (median time 5.8 months, range 2.8 to 16.7 months).

• CCR was also achieved sooner in the Gleevec arm (median time 5.6 months, range 2.2 to 16.7

months) compared with the IFN-α + ara-C arm (median time 8.4 months, range 2.8 to 16.4

months).

Reference

1. Data on file. Novartis Pharmaceuticals Corporation, East Hanover, NJ.